Key result
Mouse NIH 3T3 fibroblasts encapsulated in 2% w/v Ca-alginate remained viable for 150 days and provided sustained release of VEGF at approximately 1.4 ng per million cells over 3 days, which was significantly lower than nonencapsulated monolayers.
Why the study?
Does encapsulation of fibroblasts in Ca-alginate hydrogel provide sustained release of VEGF in an in vitro model?
Population
Mouse NIH 3T3 fibroblasts in an in vitro model
Design
Preclinical
Follow-up
Up to 150 days
Authors
Loading...
Encapsulated fibroblasts sustain VEGF release in vitro; hypothesis-generating for tissue-engineered revascularization post-MI.
Does encapsulation of fibroblasts in Ca-alginate hydrogel provide sustained release of VEGF in an in vitro model?
Absolute Event Rate: 1.4% vs 5.5%
p-value: p=<0.05
Fibroblasts encapsulated in Ca-alginate hydrogel maintain long-term viability and provide sustained release of VEGF, demonstrating potential as a tissue engineering strategy for cardiac revascularization after myocardial infarction.
Hunt et al. (2012) studied Myocardial Infarction (In Vitro Model). Calcium-Alginate Hydrogel-Encapsulated Fibroblasts vs. Nonencapsulated fibroblast monolayers was evaluated on VEGF secretion over 3 days (p=<0.05). Mouse NIH 3T3 fibroblasts encapsulated in 2% w/v Ca-alginate remained viable for 150 days and provided sustained release of VEGF at approximately 1.4 ng per million cells over 3 days, which was significantly lower than nonencapsulated monolayers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: